Terramera Inc. Overview
Listing status: The input list describes Terramera as a public company. That is incorrect. Terramera describes itself as privately held [Terramera "About Us" page], and no exchange listing, ticker, ISIN or CUSIP exists for it.
Terramera began in 2010 as a neem-based biopesticide start-up. Its first products were consumer and professional bed-bug sprays, the Proof and CIRKIL lines. Over the following decade it built a large patent estate in formulation and active-ingredient delivery, centred on its Actigate™ technology and the IP it bought from Exosect. It raised one of Canada's largest agtech venture rounds (US$48.5M Series B, 2019) on a public goal of cutting synthetic chemical loads in agriculture by 80% by 2030. A financing collapse in mid-2022 forced a strategic reset. Under CEO Nate Kelly, Terramera restructured into what BetaKit (March 2026) describes as an IP holding company. It now incubates and holds equity in independent spinouts: Miraterra, which does soil chemistry, biology and remote sensing, and Catalera BioSolutions, which develops biological fungicides, insecticides and miticides. Terramera's value now rests mainly on its patent portfolio (company-stated at more than 350 patents), its minority and partial stakes in these ventures, and its Indian neem supply operation. Operating revenue is now largely earned by the spinouts.
Company's own description. Terramera's current "About Us" page says the company advances agricultural innovation by building independent, science-based companies. It names Catalera BioSolutions and Miraterra as its spinouts and confirms it is privately held and based in Vancouver. An earlier version of the same page described two internal divisions. The first was "Green Chemistry Solutions," a formulation platform combining machine-learning design, more than 350 delivery and stabilization patents, and rapid prototyping. The second was Miraterra, a soil measurement platform claiming parts-per-million accuracy [Terramera About Us, both versions].
Independent characterization. Terramera has gone through three business models.
-
2010 to about 2016: consumer and professional biopesticides. The company sold neem-based sprays for bed bugs and dust mites at retail (Proof, sold through retailers including Target) and to pest-control professionals (CIRKIL). It integrated backward into neem supply by buying Plasma Power, an Indian cold-pressed neem oil producer [TechCrunch 2019; PCT Online].
-
2016 to 2022: agricultural biologicals and an AI/formulation platform. Most staff moved to agriculture; by 2019 more than 90% of the team was focused on it [BCBusiness 2019]. The company launched the EPA-registered RANGO (2018) and SOCORO (2023) and licensed and partnered its Actigate delivery technology. It also expanded into digital agriculture and soil-carbon measurement (the Terramera Intelligence Engine), which was heavily grant-funded.
-
2023 to present: IP holding company and venture builder. After its 2022 financing fell through, the company split its "many businesses in one" into separately financed spinouts. Miraterra (soil) launched in January 2023 and Catalera (biologicals) in May 2024. Terramera kept equity stakes, the core IP estate and the Indian neem operation [Vancouver Tech Journal, Mar 2023; BetaKit, Mar 2026].
Revenue model. Terramera has never disclosed revenue figures; the founder declined to discuss revenue in 2019 [BCBusiness 2019]. Its historical and current revenue types are:
Value-chain position. Terramera sits upstream, in active-ingredient sourcing (neem and karanja) and in formulation and delivery-technology IP. Through Catalera it reaches crop-protection products sold via distributors to growers. Through Miraterra it reaches measurement infrastructure sold mainly to soil labs rather than directly to farmers [AgTechNavigator, Jul 2025].
Customer types and end markets. These are specialty-crop and row-crop growers (organic and conventional), pest-management professionals, consumers (household pests), agricultural input companies (licensing and co-development), soil-testing laboratories, agronomists, and food and supply-chain companies (Miraterra's "soil-to-table" positioning). Government agencies are a further group, as funders and potential standard-setters for soil carbon.
Strategy
Stated strategy themes.
Historical (2019–2022): "Unlock the intelligence in nature." Reduce global synthetic chemical loads in agriculture by 80% while raising farm productivity by 20% by 2030 [Built In; ImpactAlpha 2019]. Use AI, computational chemistry and Actigate to make biologicals competitive with synthetics. Build a soil-carbon measurement standard to enable farm carbon credits [SDTC release 2021].
Current (2023 onward): Make agriculture "work with nature" by building independent companies grounded in deep science. Turn the patent estate into focused, separately capitalized ventures [Terramera About Us; BetaKit 2026]. In 2023 Manhas described the earlier structure as effectively running many businesses inside one company, and said this hurt market understanding and fundraising [Vancouver Tech Journal 2023].
ESG commitments. The 80/20 by 2030 pledge remains on Terramera's legacy materials. No updated progress metrics have been published.
Cost programs. The 2023 restructuring under Kelly is confirmed [BetaKit 2026], but no targets or savings were disclosed.
Medium-term financial targets / guidance: None published.
Products & Services
Crop protection (now commercialized by Catalera BioSolutions)
| Product | Description and capabilities | Target customer | Launch / registration | Pricing | Source |
|---|---|---|---|---|---|
| RANGO® | Broad-spectrum plant-based insecticide, fungicide and miticide built on a proprietary formulation. Controls aphids, mites, thrips, worms, whiteflies, botrytis, fusarium and powdery mildew. Zero-day pre-harvest interval; 4-hour re-entry. OMRI-listed. | Specialty-crop growers (vegetables, fruit, berries and grapes, tree crops, ornamentals, greenhouse) | EPA registration and launch 20 Nov 2018; California approval Oct 2019 | — | Terramera press release 2018; AgbioInvestor |
| SOCORO® | Broad-spectrum biological insecticide, miticide and fungicide using neem oil plus other bio-actives. For organic and conventional growers. Not registered in Canada as of 2023. | Soybean, corn and row-crop growers (US) | US launch Apr 2023 | — | BIV, Apr 2023 |
| TRIFECTO® | Biopesticide containing 70% cold-pressed neem oil on a proprietary inert carrier that improves in-tank stability | Growers in Mexico | COFEPRIS approval c. 2024 | — | CB Insights news; Techcouver 2024 |
| Vaporpad® | Professional bed-bug treatment | Pest-management professionals | Date n/d | — | Techcouver, Sep 2024 |
| Microbial bio-insecticide (pipeline) | Microbial insecticide in development | Agriculture | Expected launch 2026 | — | Country Guide |
| Combination bio-insecticide (pipeline) | Combination biological insecticide | Agriculture | Expected commercialization 2025 (completion not confirmed) | — | Country Guide |
Consumer and professional legacy lines (Terramera-era)
| Product | Description | Customer | Period | Current status | Source |
|---|---|---|---|---|---|
| Proof® (Proof Spray; bugproof.com) | Neem-based, EPA-registered bed-bug and dust-mite spray; company claimed 100% efficacy against bed bugs and eggs | Consumers via retailers including Target | c. 2013 onward | — | BioSpace (S2G release); TechCrunch 2019 |
| CIRKIL® (cirkil.com) | Professional-grade neem-based pest-control products | Pest-control operators | c. 2014 onward | — | BioSpace; PCT Online |
| neem.com products | Neem consumer and raw-material sales | Consumers and manufacturers | 2010s | — | BioSpace |
Raw materials (Terramera Biosciences India)
| Product | Specification (company-stated) | Customer | Source |
|---|---|---|---|
| 100% pure cold-pressed neem oil | Patented cold-press extraction; filtered to 5 microns; azadirachtin content stated above 3,000 ppm | Biopesticide formulators, fertilizer and agri-input firms, cosmetics | Shifair 2026 |
| Neem kernel cake (powder and pellet) | Organic soil amendment | Fertilizer and agricultural buyers | Shifair 2026 |
| Karanja oil and cake | Karanjin content stated above 20,000 ppm | Agri-inputs | Shifair 2026; PMP |
Technology platforms (Terramera-held IP, licensed to or used by spinouts)
| Platform | Description | Year | Source |
|---|---|---|---|
| Actigate™ Targeted Performance technology | Green-chemistry delivery that carries natural or synthetic actives directly into target cells, so less active ingredient is needed and biologicals perform better | Public from c. 2018–2019 | ImpactAlpha 2019; Western Producer 2020 |
| Inspirium® | Earlier proprietary technology for stabilizing and delivering plant biochemicals such as neem | c. 2016 | BioSpace (S2G release) |
| Exosect delivery platform (incl. Entostat-derived tech) | About 134 patents and applications for delivering crop-protection actives, including organic-compatible compositions | Acquired May 2019 | Terramera press release; Dealroom |
| RNAi technology (ex-CCI) | RNA-interference technology for crop protection | Acquired Mar 2019 | AgbioInvestor |
| Plant Intelligence Engine™ | AI-based screening of novel adjuvants | c. 2021 | CB Insights (MBI release excerpt) |
| Terramera Intelligence Engine | Sensors, imaging and analytics for soil-carbon quantification; target cost of about US$5 per acre | 2021–2022 | BetaKit 2022; Terramera press release 2021 |
Soil intelligence (now Miraterra)
| Offering | Description | Customer | Launch | Source |
|---|---|---|---|---|
| enrichSoil (original product) | Real-time soil analysis of N, P, K and C. The company claimed 99% accuracy versus 40–60% for conventional methods. | Farmers, agronomists | Limited commercial launch planned 2023 | Techcouver, Jan 2023 |
| Miraterra Digitizer | Raman-spectroscopy instrument using multiple lasers, signal processing and AI to measure soil chemistry | Soil-testing labs worldwide | 2023 onward | BetaKit 2026; AgTechNavigator 2025 |
| Trace Genomics products (acquired) | DNA-based soil biology testing, including shotgun metagenomics and pathogen panels | Legacy Trace customers, e.g., Terraforma | Acquired Jul 2025 | PR Newswire 2025 |
| Remote sensing stack | Satellite and LIDAR imaging decoded with AI | Agribusiness, policymakers | 2025–2026 | BetaKit 2026 |
Financial Narrative
Disclosure status. Terramera is privately held and has not published income statements, balance sheets or cash-flow statements for any fiscal year. Its fiscal year end is also undisclosed. Every line below is therefore "n/d". The tables are kept for automation compatibility.
Income statement
Revenue CAGR: n/d.
Disclosed capital inflows (best available financial proxy)
The only quantitative financial data in the public domain are financing and grant announcements. They are shown by calendar year in original currency. Rows mix currencies, so the currency is stated in each row label. Rounds raised by spinouts are listed separately because they did not flow to Terramera's own balance sheet, apart from the enrichAg seed, which was structured at subsidiary level.
Notes:
-
The 2019 Series B is reported as US$45M at announcement [BusinessWire, Sep 2019], extended to US$48.5M by ArcTern [Techcouver]. Canadian-dollar reports conflict: C$59.5M [BetaKit 2019] and C$64.1M [BetaKit 2022].
-
2020: C$0.3M Innovate BC Ignite award, held jointly with SFU [Terramera newsroom].
-
2022: C$1M BC ICE Fund plus C$2M AgriClean Tech [BetaKit 2022; Vancouver Tech Journal 2023].
-
2023 bridge note amount: n/d [Vancouver Tech Journal, Mar 2023].
-
Miraterra extension: closed October 2025; FCC also provided undisclosed debt; Miraterra's total funding is nearly C$40M [BetaKit, Mar 2026].
-
Catalera: initial close Sep 2024; Canadian-dollar coverage puts the first tranche at C$8.8M (US$6.5M) [BetaKit 2024].
Commentary. No audited trend analysis is possible. The qualitative pattern is still clear. Terramera was capital-intensive and grant-supported from 2019 to 2022, with heavy R&D across delivery chemistry, AI and soil sensing, and headcount near 135. It then hit a liquidity crisis when a financing failed in summer 2022 [Vancouver Tech Journal]. The response was to cut the corporate cost base sharply (third-party headcount profiles imply a fall from about 135 to about 29) and move capital needs to spinouts with their own investors. Within the group, revenue generation now sits mainly at Catalera (in-market biopesticides) and Miraterra (which recently began generating revenue and inherited what its CEO called meaningful revenue from Trace Genomics [BetaKit 2026; AgTechNavigator 2025]). Terramera's own accounts most likely reflect India neem operations, any licensing income, and its equity investments, though none of this has been disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship to Terramera | Activity | Leadership | Source |
|---|---|---|---|---|
Terramera, Inc. (Vancouver) | Parent / IP holding company | Holds patent estate, equity stakes, India subsidiary | Nate Kelly (CEO), Karn Manhas (Exec. Chair) | BetaKit 2026 |
Miraterra Technologies Corporation (formerly enrichAg Technologies) | Partially owned subsidiary; originally majority-owned (Jan 2023); current stake n/d | Soil chemistry (Raman-spectroscopy Digitizer), soil biology (ex-Trace Genomics metagenomics), satellite and LIDAR remote sensing | Nate Kelly (CEO); about 50 staff | BetaKit 2026; Techcouver 2023 |
Catalera BioSolutions Inc. | Independent spinout; Terramera is a shareholder (stake n/d) | Biological fungicides, insecticides, miticides; RANGO, SOCORO, Vaporpad, TRIFECTO | Matthew Dahabieh (CEO); Nate Kelly (Chair) | BetaKit 2024; BetaKit 2026 |
Terramera Biosciences (India) Private Limited | Subsidiary (ownership % n/d) | Cold-pressed neem oil, neem kernel cake, karanja oil and cake | — | Shifair 2026 |
Balance Sheet and Key Financials
| Inflow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Terramera equity: Series B total (USD Mn) | 48.5 | 0 | 0 | 0 | 0 | 0 | 0 |
Terramera growth capital: BDC (CAD Mn) | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
Terramera government grants (CAD Mn) | — | 0.3 | 7.9 | 3 | 0 | 0 | 0 |
Terramera bridge note (CAD Mn) | 0 | 0 | 0 | 0 | — | 0 | 0 |
Miraterra / enrichAg equity (USD Mn) | 0 | 0 | 0 | 0 | 6 | 0 | — |
Miraterra seed extension (CAD Mn) | 0 | 0 | 0 | 0 | 0 | 0 | 16 |
Catalera Series A target (USD Mn) | 0 | 0 | 0 | 0 | 0 | 8 | 0 |
Geography Overview
| Geography | Activity | Evidence |
|---|---|---|
United States | Main crop-protection market: RANGO (EPA 2018; California 2019) and SOCORO (2023). Consumer Proof retail. Miraterra lab in Ames, Iowa, and Midwest business development. | Terramera and Catalera releases; Miraterra job postings; PR Newswire 2025 |
Canada | HQ, R&D, greenhouse and growth chambers; soil-carbon pilots funded by SDTC and BC. SOCORO was not registered in Canada as of 2023. | BIV 2023; Terramera releases |
Mexico | TRIFECTO registered by COFEPRIS | CB Insights news; Techcouver 2024 |
India | Neem and karanja production via Terramera Biosciences (India), Chennai | Shifair 2026 |
Global (labs) | Miraterra sells its Digitizer to soil labs worldwide instead of selling direct to farmers | AgTechNavigator 2025 |
Capital Markets
| Metric | FY2021 |
|---|---|
Item | Status |
Analyst consensus | None (no coverage) |
Dividend policy | None disclosed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | n/d. A 2023 bridge note exists (terms n/d); FCC debt sits at Miraterra, not the parent [BetaKit 2026]. |
Private valuation marks | n/d for Terramera. Dealroom shows an algorithmic enterprise-value range of US$26–39M for Catalera; this is a model estimate, not a transaction price. |
Secondary markets | Caplight lists Catalera; no pricing visible |
Analyst Conclusions
Management guidance: None published at the Terramera level.
-
Miraterra plans to use its 2025 extension to accelerate Digitizer deployment, demonstrate full-stack soil measurement and advance its technology [BetaKit 2026].
-
Catalera targets new biological launches, including a microbial bio-insecticide in 2026 [Country Guide].
Consensus growth expectations: None (no coverage).
Bull case
-
Option value in two focused ventures. Miraterra now combines chemistry, biology and remote sensing, has about 50 staff, is generating revenue, and has nearly C$40M raised from credible investors. A successful scale-up or strategic sale would revalue Terramera's partial stake.
-
Monetizable IP. More than 350 delivery and stability patents, plus the Exosect estate, give the company licensing and sale leverage as majors race to make biologicals perform consistently. The 2021 Marrone collaboration is a proof point.
-
Lean parent with real assets. After restructuring, the parent's cost base appears much lower (about 29 staff per a third-party profile), while it keeps an operating Indian neem business and equity in Catalera's in-market products (RANGO, SOCORO, TRIFECTO, Vaporpad).
Bear case
-
Opaque and diluted economics. No financials, unknown stake sizes, and repeated subsidiary rounds mean Terramera shareholders may own a shrinking slice behind investors with liquidation preferences.
-
Track record of over-promising. The 80/20-by-2030 goal, the C$730M Global Centre and soil-carbon cost targets have no published progress. The 2022 financing collapse shows fragility.
-
Crowded, capital-hungry markets. Biologicals face efficacy skepticism and competition from majors with deep pockets. Soil MRV depends on carbon-credit demand that has disappointed, and Catalera's US$8M Series A is small against registration costs.
Key catalysts and monitorables (next 12 months)
Analyst verdict.
Terramera, Inc. is not the listed company the input list suggests. It is a private Vancouver venture builder and IP holding company, and analysis has to treat it as such. For about a decade it was a much-praised Canadian agtech champion. It raised a US$48.5M Series B, won national innovation awards and set out a sweeping mission to cut synthetic pesticide use 80% by 2030. Much of that vision depended on continuous access to capital. When a financing fell through in summer 2022, the company's spread across consumer pest control, agricultural biologicals, AI discovery, soil carbon and a proposed C$730M research centre became a weakness.
The restructuring since 2023 under CEO Nate Kelly is a reasonable response. Moving soil intelligence into Miraterra and biologicals into Catalera gave each business its own investors, narrower goals and a credible management team. It also left the parent as a holder of patents and partial equity stakes. Miraterra is the more visible success: it bought Trace Genomics' assets in 2025, closed a C$16M extension, and now has a revenue-generating chemistry, biology and remote-sensing stack. Catalera has real registered products but a modest capital base for a regulation-heavy industry.
For an investor, counterparty or acquirer, Terramera's value depends on three unknowns: the size and preference ranking of its stakes in the spinouts, the licensing yield of its 350-plus patents, and the economics of its Indian neem business. None of these is disclosed. Without them, no defensible valuation can be set. On balance, Terramera is best viewed as a speculative, illiquid holding vehicle with real underlying technology and meaningful upside if either spinout reaches a strategic exit, alongside material dilution and transparency risks. Due diligence should start with cap-table and IP-assignment documents. Public data cannot settle the question.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background | Source |
|---|---|---|---|---|
Nate Kelly | CEO, Terramera; CEO and board member, Miraterra; Chair, Catalera | Since Mar 2023 | About 20 years of building and scaling companies including Tesla (led Model S supply chain), Microsoft and Glowforge; agricultural-community background in Colombia, the US and Canada; based in Santa Barbara as of 2023 | Vancouver Tech Journal 2023; BetaKit 2026; AgTechNavigator 2025 |
Karn Manhas | Founder; Executive Chair | Founder 2010; CEO 2010–Mar 2023; Exec. Chair since Mar 2023 (current status not reconfirmed in 2026 sources) | Former BC MLA (elected 2001 at 24); law degree; McGill; biology background; board member of Qu Biologics | Vancouver Tech Journal 2023; BCBusiness; Techcouver |
Jeff Booth | Senior independent non-executive director (from Mar 2023); previously Chairman (from Sep 2019) | Board since at least 2019 | Tech entrepreneur and author | ImpactAlpha 2019; Vancouver Tech Journal 2023 |
Matthew Dahabieh | Former SVP and Head of Green Chemistry Solutions; now CEO of Catalera | Left with the Catalera spinout, May 2024 | Formulation and biologicals leader | BetaKit 2024 |
Travis Good | Former CTO | c. 2020 | — | BetaKit 2020 |
Graeme Herring | Former VP, Intellectual Property Strategy | c. 2019 | — | Terramera press release 2019 |
Craig Hughes | Former President | Dates n/d | Ex-TELUS, Siemens, QuickMobile | MarketScreener |
Executive Leadership Team — Dr. Adrian Percy
| Name | Body | Background | Source |
|---|---|---|---|
Dr. Adrian Percy | Chair, Science & Technology Advisory Council | Former global head of R&D, Bayer Crop Science; CTO of UPL | Techcouver |
Dr. Markita Landry | Science & Technology Advisory Council | Academic scientist | Techcouver |
Tom Chi | Science & Technology Advisory Council | Later founding partner of At One Ventures (Miraterra lead investor) | Techcouver; Fertilizer Daily 2025 |
Nancy Roman | Strategic Advisory Board | Food-policy executive | Techcouver |
Stewart Beck | Strategic Advisory Board | Former President and CEO, Asia Pacific Foundation of Canada; 31-year diplomat | Techcouver |
Santa Ono | Strategic Advisory Board | University president | Techcouver |
Unnamed climate-policy expert | Strategic Advisory Board | — | Techcouver |
Major Shareholders
| Investor | Type | Rounds | Stake |
|---|---|---|---|
S2G Ventures / S2G Investments | VC (Chicago) | Series A lead (2016); Series B co-lead (2019); Catalera Series A lead; Miraterra investor | — |
Ospraie Ag Science | Strategic ag investor | Series B co-lead (2019) | — |
BDC Capital | Crown corporation | C$13M growth capital (2019) | — |
ArcTern Ventures | Cleantech VC | US$3.5M Series B extension | — |
Export Development Canada | Crown corporation | Listed investor | — |
Innovate BC | Provincial agency | Grants | — |
Harmonix Fund | Fund | Listed investor | — |
At One Ventures | Climate VC | enrichAg/Miraterra seed lead (2023) and extension lead (2025) | Subsidiary level; n/d |
Sitka Foundation; iSelect; Farm Credit Canada | Foundation, VC, crown lender | Miraterra investors | Subsidiary level; n/d |
Karn Manhas | Founder / insider | — | — |
Competitive Landscape
Key Competitors
| Competitor | Type | Relevance |
|---|---|---|
Bayer Crop Science | Global major | Biologicals pipeline and partnerships; formulation scale |
Syngenta (Syngenta Biologicals) | Global major | Large biologicals portfolio |
Corteva Agriscience | Global major | Expanded biologicals via acquisitions (Stoller, Symborg) |
BASF Agricultural Solutions | Global major | Biologicals and formulation |
FMC Corporation | Major | Plant Health / biologicals unit |
UPL (NPP – Natural Plant Protection) | Major | Natural and biological solutions; ex-CTO Adrian Percy was a Terramera adviser |
Bioceres / ProFarm (formerly Marrone Bio) | Mid-cap | Direct biopesticide competitor and former Terramera partner |
Certis Biologicals | Private / subsidiary | Neem-based and microbial biopesticides in the US |
Koppert | Private | Biological control leader |
Vestaron; Provivi; Solasta Bio | Venture-stage | Peptide, pheromone and novel bio-insecticides |
Neem-oil formulators (e.g., AzaMax/Parry-type products) | Various | Direct neem-based competition |
Pattern Ag | Venture | Soil DNA and biology-based agronomy |
Yard Stick PBC | Venture | In-field soil-carbon spectroscopy probe |
EarthOptics | Venture | Ground-penetrating sensing for soil carbon and compaction |
Perennial; Regrow | Venture | Remote-sensing and model-based soil carbon MRV |
Conventional soil labs (e.g., Waypoint, Ward) | Incumbent | Wet-chemistry testing; also a possible channel for the Digitizer |
Peer Comparison FY2024
| Metric | Terramera (FY n/d) | Bayer Crop Science (FY2024) | Corteva (FY2024) | FMC (FY2024) |
|---|---|---|---|---|
Revenue | — | about EUR 22.3bn | about USD 16.9bn | about USD 4.2bn |
Revenue growth | — | Negative | Slightly negative | Negative |
EBITDA margin | — | Low-20s % | High-teens % | Low-20s % |
R&D intensity | n/d (historically R&D-led; more than half of 2019 hiring plan was R&D) | About 10% of sales | About 8% of sales | About 7% of sales |
Recent Developments
Most developments occur at the spinout level.
Not found in the window: * Terramera-level financing, executive changes, litigation, regulatory actions, layoffs or product registrations.



